Tokyo Tape
Sign in
← PeptiDream

Quarterly report · Q3

4587.TEDINET S100S80C
Period2023-01-01 → 2023-09-30
Filed2023-11-10
StandardIFRS
ConsolidatedYes
Data checks16 of 16 passed
Key figures · 62
MetricValuePeriodScopeSource row
Revenue¥22.5bn2023-01-01 → 2023-09-30Cons.Revenue IFRS
Revenue¥13.1bn2023-07-01 → 2023-09-30dCons.Revenue IFRS
Revenue¥26.9bn2022-01-01 → 2022-12-31Cons.Revenue IFRS (5-year summary)
Revenue¥11.2bn2022-01-01 → 2022-09-30Cons.Revenue IFRS
Revenue¥6.2bn2022-07-01 → 2022-09-30dCons.Revenue IFRS
Operating income¥6.8bn2023-01-01 → 2023-09-30Cons.Operating profit loss IFRS
Operating income¥7.7bn2023-07-01 → 2023-09-30dCons.Operating profit loss IFRS
Operating income−¥427m2022-01-01 → 2022-09-30Cons.Operating profit loss IFRS
Operating income¥1.2bn2022-07-01 → 2022-09-30dCons.Operating profit loss IFRS
Profit before tax¥4.7bn2023-01-01 → 2023-09-30Cons.Profit loss before tax IFRS
Profit before tax¥5.8bn2023-07-01 → 2023-09-30dCons.Profit loss before tax IFRS
Profit before tax¥6.7bn2022-01-01 → 2022-12-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax−¥369m2022-01-01 → 2022-09-30Cons.Profit loss before tax IFRS
Profit before tax¥1.2bn2022-07-01 → 2022-09-30dCons.Profit loss before tax IFRS
Net income (owners)¥3.5bn2023-01-01 → 2023-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥4.3bn2023-07-01 → 2023-09-30dCons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥7.6bn2022-01-01 → 2022-12-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)−¥187m2022-01-01 → 2022-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥946m2022-07-01 → 2022-09-30dCons.Profit loss attributable to owners of parent IFRS
Net income¥3.5bn2023-01-01 → 2023-09-30Cons.Profit loss IFRS
Net income¥4.3bn2023-07-01 → 2023-09-30dCons.Profit loss IFRS
Net income¥7.6bn2022-01-01 → 2022-12-31Cons.Profit loss IFRS (5-year summary)
Net income−¥187m2022-01-01 → 2022-09-30Cons.Profit loss IFRS
Net income¥946m2022-07-01 → 2022-09-30dCons.Profit loss IFRS
Total assets¥66.1bnat 2023-09-30Cons.Assets IFRS
Total assets¥63.9bnat 2022-12-31Cons.Assets IFRS
Total assets¥51.3bnat 2022-09-30Cons.Total assets IFRS (5-year summary)
Total liabilities¥28.6bnat 2023-09-30Cons.Liabilities IFRS
Total liabilities¥31.8bnat 2022-12-31Cons.Liabilities IFRS
Net assets / equity¥37.5bnat 2023-09-30Cons.Equity IFRS
Net assets / equity¥32.0bnat 2022-12-31Cons.Equity IFRS
Net assets / equity¥24.5bnat 2022-09-30Cons.Equity IFRS
Net assets / equity¥25.4bnat 2021-12-31dCons.Equity IFRS
Equity (owners)¥37.5bnat 2023-09-30Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥32.0bnat 2022-12-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥24.5bnat 2022-09-30Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥13.6bnat 2023-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥5.2bnat 2022-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥4.6bnat 2022-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥11.7bnat 2021-12-31dCons.Cash and cash equivalents IFRS
Operating cash flow¥9.2bn2023-01-01 → 2023-09-30Cons.Net cash provided by used in operating activities IFRS
Operating cash flow−¥83m2022-01-01 → 2022-12-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow−¥1.4bn2022-01-01 → 2022-09-30Cons.Net cash provided by used in operating activities IFRS
Investing cash flow¥1.8bn2023-01-01 → 2023-09-30Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥27.4bn2022-01-01 → 2022-12-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥27.0bn2022-01-01 → 2022-09-30Cons.Net cash provided by used in investing activities IFRS
Financing cash flow−¥2.9bn2023-01-01 → 2023-09-30Cons.Net cash provided by used in financing activities IFRS
Financing cash flow¥20.8bn2022-01-01 → 2022-12-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow¥20.9bn2022-01-01 → 2022-09-30Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥27.32023-01-01 → 2023-09-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥32.952023-07-01 → 2023-09-30dCons.Basic earnings loss per share IFRS
EPS (basic)¥58.192022-01-01 → 2022-12-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥-1.442022-01-01 → 2022-09-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥7.282022-07-01 → 2022-09-30dCons.Basic earnings loss per share IFRS
EPS (diluted)¥27.272023-01-01 → 2023-09-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥32.912023-07-01 → 2023-09-30dCons.Diluted earnings loss per share IFRS
EPS (diluted)¥58.142022-01-01 → 2022-12-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥-1.442022-01-01 → 2022-09-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥7.282022-07-01 → 2022-09-30dCons.Diluted earnings loss per share IFRS
Equity ratio56.7%at 2023-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio50.2%at 2022-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio47.7%at 2022-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 26
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2023-01-01 → 2023-09-30−¥63m
Reconciling Itemsreconcilingrevenue intersegment2023-01-01 → 2023-09-30−¥63m
jpcrp040300-q3r_E27486-000Drug Discovery And Development Businessreportable segmentrevenue2023-01-01 → 2023-09-30¥10.7bn
jpcrp040300-q3r_E27486-000Drug Discovery And Development Businessreportable segmentrevenue external2023-01-01 → 2023-09-30¥10.7bn
jpcrp040300-q3r_E27486-000Drug Discovery And Development Businessreportable segmentsegment profit2023-01-01 → 2023-09-30¥6.6bn
jpcrp040300-q3r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue2023-01-01 → 2023-09-30¥11.9bn
jpcrp040300-q3r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue external2023-01-01 → 2023-09-30¥11.8bn
jpcrp040300-q3r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue intersegment2023-01-01 → 2023-09-30¥63m
jpcrp040300-q3r_E27486-000Radiopharmaceuticals Businessreportable segmentsegment profit2023-01-01 → 2023-09-30¥247m
—segment totalrevenue2023-01-01 → 2023-09-30¥22.6bn
—segment totalrevenue external2023-01-01 → 2023-09-30¥22.5bn
—segment totalrevenue intersegment2023-01-01 → 2023-09-30¥63m
—segment totalsegment profit2023-01-01 → 2023-09-30¥6.8bn
Reconciling Itemsreconcilingrevenue2022-01-01 → 2022-09-30−¥8m
Reconciling Itemsreconcilingrevenue intersegment2022-01-01 → 2022-09-30−¥8m
jpcrp040300-q3r_E27486-000Drug Discovery And Development Businessreportable segmentrevenue2022-01-01 → 2022-09-30¥3.6bn
jpcrp040300-q3r_E27486-000Drug Discovery And Development Businessreportable segmentrevenue external2022-01-01 → 2022-09-30¥3.6bn
jpcrp040300-q3r_E27486-000Drug Discovery And Development Businessreportable segmentsegment profit2022-01-01 → 2022-09-30−¥197m
jpcrp040300-q3r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue2022-01-01 → 2022-09-30¥7.6bn
jpcrp040300-q3r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue external2022-01-01 → 2022-09-30¥7.6bn
jpcrp040300-q3r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue intersegment2022-01-01 → 2022-09-30¥8m
jpcrp040300-q3r_E27486-000Radiopharmaceuticals Businessreportable segmentsegment profit2022-01-01 → 2022-09-30¥183m
—segment totalrevenue2022-01-01 → 2022-09-30¥11.2bn
—segment totalrevenue external2022-01-01 → 2022-09-30¥11.2bn
—segment totalrevenue intersegment2022-01-01 → 2022-09-30¥8m
—segment totalsegment profit2022-01-01 → 2022-09-30−¥14m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 601
ItemContextValueUnit
Deferred tax assets IFRSPrior1YearInstant3435235000JPY
Deferred tax assets IFRSCurrentQuarterInstant3461879000JPY
Retirement benefit asset nca IFRSPrior1YearInstant65441000JPY
Retirement benefit asset nca IFRSCurrentQuarterInstant69535000JPY
Other non current assets nca IFRSPrior1YearInstant41218000JPY
Other non current assets nca IFRSCurrentQuarterInstant52079000JPY
Non current assets IFRSPrior1YearInstant38792486000JPY
Non current assets IFRSCurrentQuarterInstant38508478000JPY
Assets IFRSPrior1YearInstant63865200000JPY
Assets IFRSCurrentQuarterInstant66103857000JPY
Trade and other payables cl IFRSPrior1YearInstant4080097000JPY
Trade and other payables cl IFRSCurrentQuarterInstant6507659000JPY
Borrowings cl IFRSPrior1YearInstant2690653000JPY
Borrowings cl IFRSCurrentQuarterInstant2194629000JPY
Other financial liabilities cl IFRSPrior1YearInstant344882000JPY
Other financial liabilities cl IFRSCurrentQuarterInstant275957000JPY
Income taxes payable cl IFRSPrior1YearInstant2325030000JPY
Income taxes payable cl IFRSCurrentQuarterInstant844699000JPY
Provisions cl IFRSPrior1YearInstant27649000JPY
Provisions cl IFRSCurrentQuarterInstant26273000JPY
Contract liabilities cl IFRSPrior1YearInstant669757000JPY
Contract liabilities cl IFRSCurrentQuarterInstant985407000JPY
Other current liabilities cl IFRSPrior1YearInstant892332000JPY
Other current liabilities cl IFRSCurrentQuarterInstant643813000JPY
Total current liabilities IFRSPrior1YearInstant11030403000JPY
Total current liabilities IFRSCurrentQuarterInstant11478440000JPY
Borrowings ncl IFRSPrior1YearInstant18357797000JPY
Borrowings ncl IFRSCurrentQuarterInstant16711244000JPY
Other financial liabilities ncl IFRSPrior1YearInstant2327082000JPY
Other financial liabilities ncl IFRSCurrentQuarterInstant339768000JPY
Retirement benefit liability ncl IFRSPrior1YearInstant108450000JPY
Retirement benefit liability ncl IFRSCurrentQuarterInstant113038000JPY
Non current labilities IFRSPrior1YearInstant20793330000JPY
Non current labilities IFRSCurrentQuarterInstant17164051000JPY
Liabilities IFRSPrior1YearInstant31823734000JPY
Liabilities IFRSCurrentQuarterInstant28642492000JPY
Share capital IFRSPrior1YearInstant3956738000JPY
Share capital IFRSCurrentQuarterInstant3956738000JPY
Capital surplus IFRSPrior1YearInstant4524436000JPY
Capital surplus IFRSCurrentQuarterInstant4502054000JPY
Treasury shares IFRSPrior1YearInstant-607334000JPY
Treasury shares IFRSCurrentQuarterInstant-1085546000JPY
Retained earnings IFRSPrior1YearInstant23848337000JPY
Retained earnings IFRSCurrentQuarterInstant28326759000JPY
Other components of equity IFRSPrior1YearInstant319287000JPY
Other components of equity IFRSCurrentQuarterInstant1761359000JPY
Equity attributable to owners of parent IFRSPrior1YearInstant32041465000JPY
Equity attributable to owners of parent IFRSCurrentQuarterInstant37461364000JPY
Equity IFRSPrior1YearInstant32041465000JPY
Equity IFRSCurrentQuarterInstant37461364000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 16 of 16 passed
balance sheet identityconsolidated 2022-12-31pass rounding
balance sheet identityconsolidated 2023-09-30pass rounding
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2022-01-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-07-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-01-01/2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-07-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2022-01-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2023-01-01/2023-09-30pass
statement vs summary · revenueconsolidated 2022-01-01/2022-09-30pass
statement vs summary · revenueconsolidated 2022-07-01/2022-09-30pass
statement vs summary · revenueconsolidated 2023-01-01/2023-09-30pass
statement vs summary · revenueconsolidated 2023-07-01/2023-09-30pass
statement vs summary · total assetsconsolidated 2022-12-31pass
statement vs summary · total assetsconsolidated 2023-09-30pass